Reagents Drop Shipment
Closed Solicitation Posted
- Solicitation number
- HT940623Q0074
- Agency
- Defense Health Agency Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Place of performance
- Portsmouth, Virginia 23708, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Health Agency seeks to award a firm-fixed price supply contract to provide antisera and reagents for red blood cell typing on a quarterly drop shipment basis. The solicitation requests quotations for supplying various reagents according to the schedule in Attachment A to identify blood types, antibodies, and assist with blood product compatibility. Evaluation will be based on the offeror's capability statement, past performance references, and pricing by line item and option year. Questions are due by September 5, 2023 and proposals are due by September 7, 2023.
There is no set-aside designation. The NAICS code is 325414 and PSC code is 6515. The incumbent contractor is Immucor, Inc. The base period of performance is one year from October 1, 2023 through September 30, 2024, with four one-year option periods and potential award values up to $5 million over five years. Reagents will be shipped quarterly to the Naval Medical Center in Portsmouth, Virginia in accordance with the schedules listing over 50 products including test kits, controls, and blood grouping reagents.
Notice text
3 versions
Update #3 · Latest ·
28 August 2023: Amendment 2 - Extends the due dates for Questions from Industry to 5 September 2023 and Proposals Submissions to 7 September 2023 at 12:00pm
10 August 2023: Amendment 1 - Revises Attachment A
This solicitation is being posted to the Federal Contract Opportunities page located at https://sam.gov/. It is
understood that this is the single point of entry for posting of synopsis and solicitations to the Internet.
The Defense Health Agency Contracting Activity, Southeastern Markets Contracting Division intends to issue a Firm Fixed Price (FFP) supply contract. Supplies to be acquired include antisera for red blood cell typing utilized to assist in identifying antibodies and finding compatible blood products for transfusion. Reagents must have the ability to identify patient blood type and assist in the discovery of expected and unexpected antibodies. The supplier must also meet all FDA and AABB manufacturing standards. This requirement is being solicited in accordance with Federal Acquisition Regulation Part 13.5 – Simplified Procedures for Certain Commercial Products and Commercial Services.
Update #2 ·
10 August 2023: Amendment 1 - Revises Attachment A
This solicitation is being posted to the Federal Contract Opportunities page located at https://sam.gov/. It is
understood that this is the single point of entry for posting of synopsis and solicitations to the Internet.
The Defense Health Agency Contracting Activity, Southeastern Markets Contracting Division intends to issue a Firm Fixed Price (FFP) supply contract. Supplies to be acquired include antisera for red blood cell typing utilized to assist in identifying antibodies and finding compatible blood products for transfusion. Reagents must have the ability to identify patient blood type and assist in the discovery of expected and unexpected antibodies. The supplier must also meet all FDA and AABB manufacturing standards. This requirement is being solicited in accordance with Federal Acquisition Regulation Part 13.5 – Simplified Procedures for Certain Commercial Products and Commercial Services.
Update #1 ·
This solicitation is being posted to the Federal Contract Opportunities page located at https://sam.gov/. It is
understood that this is the single point of entry for posting of synopsis and solicitations to the Internet.
The Defense Health Agency Contracting Activity, Southeastern Markets Contracting Division intends to issue a Firm Fixed Price (FFP) supply contract. Supplies to be acquired include antisera for red blood cell typing utilized to assist in identifying antibodies and finding compatible blood products for transfusion. Reagents must have the ability to identify patient blood type and assist in the discovery of expected and unexpected antibodies. The supplier must also meet all FDA and AABB manufacturing standards. This requirement is being solicited in accordance with Federal Acquisition Regulation Part 13.5 – Simplified Procedures for Certain Commercial Products and Commercial Services.
Attachments
| File | Type | Posted |
|---|---|---|
| Solicitation HT9406Q0074 Amendment 2 28 August 2023.pdf | ||
| Solicitation HT9406Q0074 Amendment 1 10 August 2023.pdf | ||
| Attachment A Reagents and Shipment Schedule Revised 10 August 2023.pdf | ||
| Attachment A Reagents and Shipment Schedule.docx | DOCX document | |
| Solicitation HT940623Q0074_Reagent Drop Shipment 3 August 2023.pdf | ||
| Attachment B Vendor Questions Form.xlsx | XLSX spreadsheet |
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity